Free tool
FAERS Monitor: Motpoly Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216185 or its brand name (Motpoly Xr, Lacosamide). Reports on generic versions are filed under their own applications.
Reports
19,419
Serious
16,935
87% of reports
Hospitalization
7,397
Death reported
1,904
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure3,522
- drug ineffective3,033
- off label use2,359
- status epilepticus811
- dizziness741
- drug interaction736
- epilepsy720
- fall716
- somnolence701
- generalised tonic-clonic seizure674
- overdose652
- multiple-drug resistance603
- maternal exposure during pregnancy592
- death587
- fatigue578
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 197 |
| 2010 | 397 |
| 2011 | 496 |
| 2012 | 282 |
| 2013 | 205 |
| 2014 | 218 |
| 2015 | 267 |
| 2016 | 380 |
| 2017 | 660 |
| 2018 | 1,320 |
| 2019 | 1,379 |
| 2020 | 1,326 |
| 2021 | 1,806 |
| 2022 | 1,896 |
| 2023 | 2,023 |
| 2024 | 2,509 |
| 2025 | 2,360 |
| 2026 | 1,697 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple-drug resistanceSignal | 603 | 261.2 | 239.2 | 125,728 |
| status epilepticusSignal | 811 | 83.7 | 78.1 | 61,497 |
| generalised tonic-clonic seizureSignal | 674 | 45.9 | 42.6 | 28,406 |
| seizureSignal | 3,522 | 34.0 | 33.0 | 110,054 |
| epilepsySignal | 720 | 26.1 | 24.3 | 16,969 |
| maternal exposure during pregnancySignal | 592 | 7.2 | 6.7 | 3,168 |
| drug interactionSignal | 736 | 5.0 | 4.7 | 2,389 |
| somnolenceSignal | 701 | 3.8 | 3.5 | 1,440 |
| overdoseSignal | 652 | 3.3 | 3.0 | 1,039 |
| off label useSignal | 2,359 | 2.9 | 2.8 | 3,104 |
| drug ineffectiveSignal | 3,033 | 2.5 | 2.4 | 2,893 |
| fallSignal | 716 | 2.3 | 2.2 | 552 |
| dizziness | 741 | 1.6 | 1.5 | 175 |
| fatigue | 578 | 0.8 | 0.7 | 28 |
| death | 587 | 0.7 | 0.7 | 57 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.